The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
A new Australian service offers whole-genome sequencing and a health assessment, the Sydney Morning Herald reports.
An Australian team has sequenced and mapped the genome of a prostate cancer tumor, as the Australian Financial Review reports.
The reference bank is a sub-project of the Sydney Genomics Collaborative, and will be one of the world's largest publicly available genome banks of older healthy individuals.
The company's Irys genome mapping technology provides researchers with a non-sequencing-based tool that is essential for studying structural variation.
A team from Radboud University in the Netherlands performed a new detailed and transparent cost analysis for sequencing based on both static costs, and factors that may differ from institution to institution.
The Sydney-based genomics center is implementing diagnostic sequencing pipelines and figuring out best practices for incorporating genomics into healthcare.
The current arrangement builds on an existing agreement signed last year that allowed Garvan to use DNAnexus' platform for its genomics activities.
The WGS service will be provided by Genome.One, a new health information company owned by and based at the Garvan Institute of Medical Research in Sydney.
The Garvan Institute of Medical Research's Mark Cowley said his lab has a more than 50 percent diagnostic rate for rare, monogenic diseases.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.